The burn is still 3rd degree

I believe the current share price is still too high. Starpharma developments have been extremely delayed and the Astrazenica programs appear to have hit a sustained stop posture. Azd0466 appears to be going nowhere. Our price rose From well below $1 as the vivagel saga diminished however now it is likely back front and centre. I think 80c share price is realistic before the possibility of the fda totally rejecting vivagel approval. I believe starpharma is too frail for management to come clean and cease dep docetaxel phase 2 if it’s going wrong. We may watch it progress slowly as the sign of trouble. It should be rocketing along with 4 sites recruiting. 

I sense more trouble and after losing 40% of my wealth this post is written after great thought. I think investing in starpharma at this point is gambling.